12 Best Performing Biotech Stocks in 2022
Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in 2023, although...
Posts Tagged ‘NASDAQ:MACK’
Hedge Fund and Insider Trading News: Kyle Bass, Daniel Och, Bill Ackman, Perceptive Advisors, Schonfeld Strategic Advisors, Coatue Management, Merrimack Pharmaceuticals Inc (MACK), AMC Entertainment Holdings Inc (AMC), and More
Closely watched hedge fund manager Kyle Bass said Thursday that oil prices could rise "well north of $100" in 2022 as a lack of investment in the hydrocarbon industry meets a ...
Hedge Fund and Insider Trading News: Steve Cohen, Bill Ackman, Nicolai Tangen, Dan Loeb, Legion Partners Asset Management, Tyr Capital Partners, Archegos Capital Management, Artis Real Estate Investment Trust Unit (ARESF), Moderna Inc (MRNA), and More
BOSTON (Reuters) - Activist investor Legion Partners Asset Management LLC has nominated seven directors to sit on specialty retailer Genesco Inc’s eight-person board, according...
Where Do Hedge Funds Stand On Merrimack Pharmaceuticals Inc (MACK)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Fortress Investment Group, Fulcrum Asset Management, Guess?, Inc. (GES), Merrimack Pharmaceuticals Inc (MACK), and More
A ransomware attack against a vendor of SEI Investments Co.
Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
Is Merrimack Pharmaceuticals Inc (NASDAQ:MACK) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before ...
13D Filing: JFL Capital Management and Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Joseph F. Lawler's JFL Capital disclosed a 7.1% activist stake in Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde.
Is Merrimack Pharmaceuticals Inc (MACK) A Good Stock To Buy?
Looking for high-potential stocks? Just follow the big players within the hedge fund industry.
5 Stocks Hedge Funds Hate The Most
Insider Monkey keeps a keen eye on the activity of the top hedge funds in the world, as our research has shown that hedge funds’ long positions can deliver market-beating returns...
Merrimack Pharmaceuticals Inc (MACK) Sees Earnings Boost As FDA Accepts Application For Generic Drug
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have moved closer to introducing their generic version of Johnson & Johnson...
Here’s Why TASER International, Heron Therapeutics and Three Other Stocks Are Trading Lower on Monday
The markets have opened the fourth quarter on a negative note.
What Is Going On With These Falling Stocks?
After opening flat and falling into the red, the broader markets are now in the green this afternoon as investors weigh the overall positive start to earnings season.
Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)?
Hedge funds are not perfect. They have their bad picks just like everyone else.
Hedge Funds Have This To Say About Tuesday’s Healthcare Flops
Tuesday was a bad day for three healthcare stocks in particular.
Should You Buy Merrimack Pharmaceuticals Inc (MACK) After The 10% Surge?
Should you buy Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock today? The firm’s share price surged 10.22% on June 18 to attain a closing price of $12.19 after a heavy volume...
Two Directors at Merrimack Pharmaceuticals Inc (MACK) Acquired Almost Half a Million in Stock
June 23, two Board Directors at Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a $741 million market cap biotechnology company, spent a total of $467,787.60 in the company’s stock...
Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Hedge Funds Are Dumping EXACT Sciences Corporation (EXAS)
In the financial world, there are a multitude of gauges shareholders can use to analyze Mr. Market. Two of the most innovative are hedge fund and insider trading interest.
Hedge Funds Are Buying ACADIA Pharmaceuticals Inc. (ACAD)
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Do Hedge Funds and Insiders Love Halozyme Therapeutics, Inc. (HALO)?
Now, according to many investors, hedge funds are seen as delayed, outdated financial tools of an era lost to time.
Array Biopharma Inc (ARRY): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Merrimack Pharmaceuticals Inc (MACK), MannKind Corporation (MNKD), Synta Pharmaceuticals Corp. (SNTA): Horrendous Health-Care Stocks This Week
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks.
Dendreon Corporation (DNDN), Merrimack Pharmaceuticals Inc (MACK), Novavax, Inc. (NVAX): Three Horrendous Health-Care Stocks This Week
August might be hot for most of the country, but the first full week of the month wasn't so hot for some stocks.
GTx, Inc. (GTXI), Intuitive Surgical, Inc. (ISRG): Three Horrendous Health-Care Stocks This Week
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shareholders have had reason to party since early May, with the stock surging more than 60%.
Is Merrimack Pharmaceuticals Inc (MACK) Going to Burn These Hedge Funds?
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Hedge Funds Are Dumping Optimer Pharmaceuticals, Inc. (OPTR)
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
Here is What Hedge Funds Think About ACADIA Pharmaceuticals Inc. (ACAD)
To most market participants, hedge funds are viewed as underperforming, outdated financial vehicles of the past.
Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
To the average investor, there are a multitude of metrics market participants can use to track stocks. A pair of the most useful are hedge fund and insider trading movement.
Should You Avoid ACADIA Pharmaceuticals Inc. (ACAD)?
To most traders, hedge funds are seen as unimportant, outdated investment tools of the past.
Should You Avoid Merrimack Pharmaceuticals Inc (MACK)?
To the average investor, there are a multitude of gauges investors can use to monitor their holdings.
ACADIA Pharmaceuticals Inc. (ACAD): Insiders Are Dumping, Should You?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was in 12 hedge funds' portfolio at the end of the fourth quarter of 2012.
Should You Avoid EXACT Sciences Corporation (NASDAQ:EXAS)? – Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Array Biopharma Inc (NASDAQ:ARRY)
Is EXACT Sciences Corporation (NASDAQ:EXAS) ready to raly soon? Investors who are in the know are becoming less hopeful.
Merrimack Pharmaceuticals Inc (MACK) May Be Right For Your Portfolio
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio.
3 Events Biotech Investors Need to Watch in 2013: Vical Incorporated (VICL) and More
It's make-or-break time in 2013. That's the situation for several biotech companies with critical phase 3 trials under way.
